



Ref: JSTL/BOD/BSE/2018-19/Feb19

Date: Feb 14, 2019

To
Head - Listing Operations,
BSE Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Copy of Stand Alone and Consolidated UnAudited Financial Results for the Quarter Ended 31st December, 2018.

Ref: Scrip Code: 538837, Jeevan Scientific Technology Limited

Please find enclosed herewith a Copy of Stand Alone and Consolidated UnAudited Financial Results for the Quarter Ended 31st December, 2018 which were taken on record by the Board of Directors at their Meeting held on 14th February, 2019.


This is for your information and records,

Thanking you,

Yours truly,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED


K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)




Encl. As above

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.
STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018

Rupees in lakhs

SLNo	Particulars	3 months ended		Corresponding 3 months ended in the previous year	Year to date figures for the current period ended		Year to date figures for the Previous Year ended		Previous Year ended
		31-12-2018 Un Audited	30-09-2018 Un Audited		31-12-2017 Un Audited	31-12-2018 Un Audited	31-12-2017 Un Audited	31-03-2018 Audited	
1	Income								
	(a) Revenue From Operations	783.25	751.33	539.29	2,120.40	1,525.10	1,926.43		
	(b) Other Income	10.09	51.95	23.46	88.85	63.96	90.48		
	Total Income	793.34	803.28	562.75	2,209.25	1,589.06	2,016.91		
2	Expenses								
	(a) Cost of Material Consumed	59.75	42.11	34.72	138.76	94.99	129.87		
	(b) Purchase of stock-in-trade	-	-	-	-	-	-		
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-		
	(d) Employee benefit expense	223.47	212.30	143.06	602.79	364.87	498.52		
	(e) Finance Cost	49.75	49.06	61.86	137.49	136.54	152.58		
	(f) Depreciation and Amortisation expense	87.68	86.53	59.73	238.46	147.15	206.88		
	(g) Other Expenses	247.62	276.73	247.18	776.90	808.91	980.97		
	Total Expenses	668.27	666.73	546.55	1,894.40	1,582.46	1,968.42		
3	Profit before exceptional items and Tax	125.07	136.55	16.20	314.85	36.60	48.49		
4	Add(+)/Less(-) Exceptional items	-	-	-	-	-	-		
5	Profit before Tax	125.07	136.55	16.20	314.85	36.60	48.49		
6	Tax Expenses	38.36	-9.94	3.09	38.56	6.97	23.79		
7	Profit(Loss) for the Period from Continuing Operations	86.71	146.49	13.11	276.29	29.63	24.70		
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-		
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-		



Sl.No	Particulars	3 months ended	Preceding	Corresponding	Year to date	Year to date	Previous Year ended
		31-12-2018 Un Audited	30-09-2018 Un Audited	31-12-2017 Un Audited	31-12-2018 Un Audited	31-12-2017 Un Audited	
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	86.71	146.49	13.11	276.29	29.63	24.70
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.25	(0.39)	-	0.75	-	6.45
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.11)	(0.10)	-	(0.21)	-	(0.61)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	86.85	146.00	13.11	276.83	29.63	30.34
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	927.95	1,530.15	927.95	1,145.95
15	Other equity excluding revaluation reserve						1,124.47
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	0.57	0.95	0.14	1.81	0.32	0.27
	b) Diluted (Amount in Rupees)	0.57	0.95	0.14	1.94	0.32	0.32
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)	-	-	-	-	-	-
	b) Diluted (Amount in Rupees)	-	-	-	-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	0.57	0.95	0.14	1.81	0.32	0.27
	b) Diluted (Amount in Rupees)	0.57	0.95	0.14	1.94	0.32	0.32

Notes to the Standalone Un Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 14.02.2019 and approved by the Board of Directors of the Company at its meeting held on 14.02.2019. The results have been subjected to limited review by the statutory auditors.
- Post implementation of GST w.e.f 1st July 2017, revenues are disclosed exclusive of GST. Revenue for the period prior to 1st July 2017 included excise duty which is now subsumed in GST. Accordingly, revenue for the nine months ended 31st December 2017 and year ended 31st March 2018 are not comparable with those of the other periods presented.
- Figures for the previous periods have been rearranged wherever necessary.

Place:Hyderabad
Date: 14.02.2019



SEGMENT-WISE REVENUE RESULTS & CAPITAL EMPLOYED (Stand Alone Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER ENDED 31ST DECEMBER 2018

Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the Current period ended	Year to date figures for the Previous Year ended	Previous Year ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
SEGMENT REVENUE: (Net Sales / Income from Operations)						
a) Clinical Research Services	783.25	751.33	539.29	2,120.40	1,325.92	1,727.25
b) Information Technology Services	-	-	-	-	-	-
c) Data Management Services	10.09	51.95	23.46	88.85	199.18	199.18
d) Unallocable Income	793.34	803.28	562.75	2,209.25	1,589.06	2,016.91
Total:	793.34	803.28	562.75	2,209.25	1,589.06	2,016.91
LESS: Inter Segment revenue	-	-	-	-	-	-
Net Sales/Income from Operations.	793.34	803.28	562.75	2,209.25	1,589.06	2,016.91
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST						
a) Clinical Research Services	164.73	133.66	54.13	363.49	101.83	104.93
b) Information Technology Services	-	-	-	-	-	-
c) Data Management Services	164.73	133.66	54.13	363.49	5.66	5.66
Total:	164.73	133.66	54.13	363.49	107.49	110.59
LESS:						
i) Interest	49.75	49.06	61.39	137.49	134.85	152.58
ii) Other Un-Allocable Expenditure	-10.09	-51.95	-23.46	-88.85	-63.96	-90.48
iii) Un-Allocable Income	-	-	-	-	-	-
TOTAL PROFIT / (LOSS) BEFORE TAX	125.07	136.55	16.20	314.85	36.60	48.49

NOTES:

i) Segment Capital Employed: Fixed Assets used in the Company's business have been identified and only computers, software and work stations are shared among different segments.

Place: Hyderabad
Date: 14.02.2019


for Jeewan Scientific Technology Limited
On behalf of the Board of Directors
K. Krishna Kishore
Vice Chairman & Managing Director



JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.
CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018

Rupees in lakhs

Sl.No	Particulars	3 months ended		Corresponding 3 months ended in the previous year	Year to date figures for the Current period ended		Year to date figures for the Previous Year ended		Previous Year ended
		31-12-2018 Un Audited	30-09-2018 Un Audited		31-12-2017 Un Audited	31-12-2018 Un Audited	31-12-2017 Un Audited	31-03-2018 Audited	
1	Income								
	(a) Revenue from Operations	800.43	771.23	583.99	2,178.56	1,609.86	2,039.84		
	(b) Other Income	11.12	52.00	23.63	89.93	64.51	92.20		
	Total Income	811.55	823.23	607.62	2,268.49	1,674.37	2,132.04		
2	Expenses								
	(a) Cost of Material Consumed	59.75	42.11	34.72	138.76	94.99	129.87		
	(b) Purchase of stock-in-trade	0.00	-	-	-	-	-		
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	-	-	-	-	-		
	(d) Employee benefit expense	236.66	222.21	169.96	637.82	428.38	568.01		
	(e) Finance Cost	56.27	55.28	70.88	154.73	151.06	152.58		
	(f) Depreciation and Amortisation expense	89.12	87.97	61.17	242.77	151.41	212.15		
	(g) Other Expenses	251.50	283.30	256.43	795.05	827.31	1,033.23		
	Total Expenses	693.30	690.87	593.16	1,969.13	1,645.15	2,095.84		
3	Profit before exceptional items and Tax	118.25	132.36	14.46	299.36	29.22	36.20		
4	Add(+)/Less(-) Exceptional Items	-	-	-	-	-	-		
5	Profit before Tax	118.25	132.36	14.46	299.36	29.22	36.20		
6	Tax Expenses	38.36	-9.94	3.09	38.56	6.98	25.02		
7	Profit/(loss) for the Period from Continuing Operations	79.89	142.30	11.37	260.80	22.24	11.18		
8	Profit/(loss) from Discontinuing Operations	-	-	-	-	-	-		
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-		




[Handwritten Signature]

Sl.No	Particulars	3 months ended	Preceding	Corresponding	Year to date	Year to date	Previous Year
		31-12-2018 Un Audited	30-09-2018 Un Audited	31-12-2017 Un Audited	31-12-2018 Un Audited	31-12-2017 Un Audited	31-03-2018 Audited
10	Profit/(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit/(Loss) for the period	79.89	142.30	11.37	260.80	22.24	11.18
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.25	(0.39)	-	0.75	-	6.45
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.11)	(0.10)	-	(0.21)	-	(0.61)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	80.03	141.81	11.37	261.34	22.24	17.02
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	927.95	1,530.15	927.95	1,145.95
15	Other equity excluding revaluation reserve						1,055.46
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	0.52	0.93	0.12	1.71	0.24	0.15
	b) Diluted (Amount in Rupees)	0.52	0.93	0.12	1.83	0.24	0.18
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)	-	-	-	-	-	-
	b) Diluted (Amount in Rupees)	-	-	-	-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	0.52	0.93	0.12	1.71	0.24	0.15
	b) Diluted (Amount in Rupees)	0.52	0.93	0.12	1.83	0.24	0.18

Notes to the Consolidated Un Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 14.02.2019 and approved by the Board of Directors of the Company at its meeting held on 14.02.2019. The results have been subjected to limited review by the statutory auditors.
- Post implementation of GST w.e.f 1st July 2017, revenues are disclosed exclusive of GST. Revenue for the period prior to 1st July 2017 included excise duty which is now subsumed in GST. Accordingly, revenue for the nine months ended 31st December 2017 and year ended 31st March 2018 are not comparable with those of the other periods presented.
- The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- Figures for the previous periods have been rearranged wherever necessary.
- The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Entops Solutions Pvt Ltd & Entops Inc.

Place:Hyderabad
Date:14.02.2019



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER ENDED 31ST DECEMBER, 2018

Particulars	3 months ended	Preceding	Corresponding 3	Year to date	Year to date	Previous Year
	31-12-2018	30-09-2018	months ended in the previous year	figures for the Current period ended	figures for the Previous Year ended	ended
	Un Audited	Un Audited	31-12-2017	31-12-2018	31-12-2017	31-03-2018
SEGMENT REVENUE (Net Sales / Income from Operations)						
a) Clinical Research Services	783.25	751.33	539.29	2,120.40	1,325.92	1,727.25
b) Information Technology Services	17.18	19.90	44.70	58.16	84.76	115.13
c) Data Management Services	-	-	-	-	89.93	199.18
d) Unallocable Income	11.12	52.00	23.63	89.93	64.51	90.48
Total:	811.55	823.23	607.62	2,268.49	1,674.37	2,132.04
LESS: Inter-Segment revenue	-	-	-	-	-	-
Net Sales/ Income from Operations.	811.55	823.23	607.62	2,268.49	1,674.37	2,132.04
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST						
a) Clinical Research Services	164.73	133.66	54.13	363.49	101.83	104.93
b) Information Technology Services	-1.33	1.98	7.11	0.67	6.59	(12.29)
c) Data Management Services	163.40	-	-	364.16	5.66	5.66
Total:	326.80	135.64	61.24	728.31	114.08	98.30
LESS:						
i) Interest	56.27	55.28	70.41	154.73	149.37	152.58
ii) Other Un-Allocable Expenditure	-	-	-	-	-	-
iii) Un-Allocable Income	-11.12	-52.00	-23.63	-89.93	-64.51	-90.48
TOTAL PROFIT / (LOSS) BEFORE TAX	118.25	132.36	14.46	299.36	29.22	36.20

NOTES:

i) Segment Capital Employed: Fixed Assets used in the Company's business have been identified and only computers, software and work stations are shared among different segments.

Place: Hyderabad
Date: 14.02.2019

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors
(Signature)
K. Krishna Kishore
Vice Chairman & Managing Director





Ref: JSTL/BOD/BSE/2018-19/Feb19

Date: Feb 14, 2019

To
Head - Listing Operations,
BSE Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Limited Review report of the Stand Alone and Consolidated Un-Audited
Financial Results for the Quarter Ended 31st December, 2018

Ref: Scrip Code: 538837, Jeevan Scientific Technology Limited


We are herewith enclosing the Limited Review Report issued by our Statutory Auditors relating to the Stand Alone and Consolidated Un-Audited Financial Results for the Quarter Ended 31st December, 2018 which were taken on record by the Board of Directors at their Meeting held on the 14th February, 2019.

This is for your information and records,


Thanking you,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED


K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)



Encl. As above



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
Micasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com


Limited Review Report

Review Report to The Board of Directors, Jeevan Scientific Technology Limited

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. Jeevan Scientific Technology Limited** ("the company") for the quarter ended **31st December, 2018** and the year to date from 1st April 2018 to 31st December 2018 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S


(CA. N. RAJESH)
PARTNER
M.No: 223169



Place: Hyderabad
Date: 14.02.2019



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
Micasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

Consolidated Limited Review Report

**Review Report to
The Board of Directors,
Jeevan Scientific Technology Limited**

- a) We have reviewed the accompanying statement of unaudited Consolidated financial results of **M/s. Jeevan Scientific Technology Limited** ("the company") for the quarter ended **31st December, 2018** and the year to date from 1st April 2018 to 31st December 2018 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S**



**(CA. N. RAJESH)
PARTNER
M.No: 223169**



Place: Hyderabad
Date: 14.02.2019